As a nine-time consecutive participant—a "full-attendance" exhibitor—at the China International Import Expo (CIIE), Sanofi's Dupixent® (dupilumab) has rapidly expanded its indication portfolio since its official approval in China in 2020, leveraging the CIIE's spillover effects and the tailwinds of China's drug regulatory review reform. It has now been approved for 11 indications and applicable populations, spanning three major therapeutic areas: dermatology, respiratory, and otorhinolaryngology. The drug is the world's first fully human monoclonal antibody targeting IL-4Rα, capable of simultaneously blocking IL-4 and IL-13 signaling and shutting down the type 2 inflammatory response network at its upstream source. Its cross-field indication expansion is driven by unmet clinical needs, grounded in scientific insight into the shared mechanisms of type 2 inflammation, and validated through numerous independent, rigorous clinical trials—setting an R&D benchmark for the biopharmaceutical industry of addressing an entire class of diseases based on a single target. Currently, Sanofi has launched five related real-world studies in China to supplement evidence-based data. Meanwhile, the company has jointly invested up to US$8 billion with Regeneron to expand their global alliance, co-developing novel long-acting immune antibody molecules, advancing technological iteration in type 2 inflammation-related immunotherapy, and exploring new directions for long-term chronic disease management.